Latest News for: cmv

Edit

Controlled Mechanical Ventilation (CMV) Systems: Analysis of AVE Solutions (AVE SpA)

Public Technologies 21 Jan 2026
). Understanding how to guarantee the healthiness of residential and commercial environments through efficient ventilation technologies ... The Advantages of CMV compared to Natural Ventilation ... Energy Efficiency ... Characteristics of AVE CMV Solutions.
Edit

New Chinese therapy uses immune memory to fight cancer

Syrian Arab News Agency 12 Jan 2026
These cells are generated in response to previous infections, such as cytomegalovirus (CMV), and remain dormant while retaining immune memory in most adults.
Edit

Safer Roads - Safer Winter: State leaders highlight new I-70 CMV left-lane restrictions and winter travel preparedness (Colorado Department of Transportation)

Public Technologies 04 Dec 2025
State leaders highlight new I-70 CMV left-lane restrictions and winter travel preparedness Dec. 3, 2025 - Denver Metro/Central Colorado https.//www.codot.gov/news/2025/december/i70-cmv-lane-restrictions https.//www.codot.gov/@@site-logo/siteLogo.png.
Edit

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

Nasdaq Globe Newswire 20 Nov 2025
EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in ...
Edit

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 (Form 6-K) (Evaxion A/S)

Public Technologies 20 Nov 2025
Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries ... With our AI-Immunology™ platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field.
Edit

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 (Evaxion A/S)

Public Technologies 20 Nov 2025
Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1. Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models.
  • 1
×